Search

Your search keyword '"Roubaud, G."' showing total 337 results
Start Over Author "Roubaud, G."
337 results on '"Roubaud, G."'

1. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

Author

Pignot, G., Fendler, J.P., Guy, L., Verhoest, G., Mottet, N., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Groeneveld, C.S., Pfister, C., Culine, S., Harter, V., Krucker, C., Fontugne, J., Dixon, V., Sirab, N., Bernard-Pierrot, I., de Reyniès, A., Radvanyi, F., and Allory, Y.

Published
2025
Full Text
View/download PDF

7. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

Author

Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., del Corral, A., Francis, P., Kim, W., and Efstathiou, E.

Published
2023
Full Text
View/download PDF

15. Recommandations françaises du Comité de cancérologie de l'AFU – Actualisation 2024–2026 : cancer de la prostate – traitement de la récidive et de la maladie métastatique.

Author

Ploussard, G., Dariane, C., Mathieu, R., Baboudjian, M., Barret, E., Brureau, L., Fiard, G., Fromont, G., Olivier, J., Rozet, F., Peyrottes, A., Renard-Penna, R., Sargos, P., Supiot, S., Turpin, L., Roubaud, G., and Rouprêt, M.

Abstract

Le Comité de cancérologie de l'Association française d'urologie propose une mise à jour des recommandations dans la prise en charge du cancer de la prostate (CaP) récidivé et/ou métastatique. Une revue systématique de la littérature de 2022 à 2024 a été conduite par le CCAFU concernant les éléments de prise en charge thérapeutique du CaP en récidive après traitement local ou métastatique, en évaluant les références avec leur niveau de preuve. L'imagerie moléculaire est le bilan standard de la récidive après traitement local. Sa réalisation ne doit pas retarder le traitement de rattrapage précoce. La suppression androgénique (SAd) est le pilier du traitement du CaP métastatique. L'intensification de la SAd est désormais un standard dans la prise en charge du CaP métastatique, associant au moins une hormonothérapie de nouvelle génération (HTNG). Pour les patients d'emblée métastatiques au diagnostic de haut volume, un traitement par docétaxel en plus de l'association SAd + HTNG peut être discuté pour les patients éligibles. Chez les patients avec un CaP résistant à la castration (CPRC), les inhibiteurs de PARP et radiothérapie interne vectorisée par ligands du PSMA sont de nouvelles options thérapeutiques. La combinaison et le séquençage des traitements dépendent de nombreux facteurs (caractéristiques du patient et de la maladie, lignes précédentes, statut génomique, imagerie moléculaire). Cette actualisation des recommandations françaises doit contribuer à améliorer la prise en charge des patients porteurs d'un CaP en récidive ou métastatique. The Oncology Committee of the French Urology Association is proposing updated recommendations for the management of recurrent and/or metastatic prostate cancer (PCa). A systematic review of the literature from 2022 to 2024 was conducted by the CCAFU on the elements of therapeutic management of PCa in recurrence after local or metastatic treatment, evaluating the references with their level of evidence. Molecular imaging is the standard assessment of recurrence after local treatment. It should not delay early remedial treatment. Androgen deprivation therapy (ADT) is the main stay of treatment for metastatic PCa. Intensification of ADT is now the standard treatment for metastatic PCa, involving at least one new-generation hormone therapy (ARPI). For patients with high-volume metastatic disease at the time of diagnosis, treatment with docetaxel in addition to ADT + ARPI may be discussed for eligible patients. In patients with castration-resistant PCa (CRPC), PARP inhibitors and PSMA radioligand therapy are new treatment options. The combination and sequencing of treatments depend on many factors (patient and disease characteristics, previous lines, genomic status, molecular imaging). This update of French recommendations should help to improve the management of patients with recurrent or metastatic PCa. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Recommandations françaises du comité de cancérologie de l'AFU – Actualisation 2024–2026 : cancer de la prostate – diagnostic et prise en charge de la maladie localisée.

Author

Ploussard, G., Baboudjian, M., Barret, E., Brureau, L., Fiard, G., Fromont, G., Olivier, J., Dariane, C., Mathieu, R., Rozet, F., Peyrottes, A., Roubaud, G., Renard-Penna, R., Sargos, P., Supiot, S., Turpin, L., and Rouprêt, M.

Abstract

Le but du comité de cancérologie de l'Association française d'urologie est de proposer une mise à jour des recommandations dans le diagnostic et la prise en charge du cancer de la prostate (CaP) localisé. Une revue systématique de la littérature de 2022 à 2024 a été conduite par le CCAFU concernant les éléments de diagnostic et de prise en charge thérapeutique du CaP localisé, en évaluant les références avec leur niveau de preuve. Les recommandations précisent la génétique, l'épidémiologie et les moyens diagnostiques du CaP, les notions de dépistage et de détection précoce. L'IRM, examen d'imagerie de référence du cancer localisé, est recommandée avant la réalisation de biopsies prostatiques. L'imagerie moléculaire est une option pour la réalisation du bilan d'extension. La voie transpérinéale permet de réduire les risques infectieux. La surveillance active est le traitement de référence pour les tumeurs de faible risque évolutif. Les moyens thérapeutiques sont détaillés, et recommandés en fonction des situations cliniques. Cette actualisation des recommandations françaises doit contribuer à améliorer la prise en charge du CaP localisé. The aim of the Oncology Committee of the French Urology Association is to propose updated recommendations for the diagnosis and management of localised prostate cancer (PCa). A systematic review of the literature from 2022 to 2024 was conducted by the CCAFU on the elements of diagnosis and therapeutic management of localised PCa, evaluating references with their level of evidence. The recommendations set out the genetics, epidemiology and diagnostic methods of PCa, as well as the concepts of screening and early detection. MRI, the reference imaging test for localised cancer, is recommended before prostate biopsies are performed. Molecular imaging is an option for extension assessment. The transperineal route reduces the risk of infection. Active surveillance is the standard treatment for tumours with a low risk of progression. Therapeutic methods are described in detail, and recommended according to the clinical situation. This update of French recommendations should help to improve the management of localised PCa. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

Author

Pignot, G., primary, Margue, G., additional, Bigot, P., additional, Lang, H., additional, Balssa, L., additional, Roubaud, G., additional, Borchiellini, D., additional, Bensalah, K., additional, Schlürmann, F., additional, Ladoire, S., additional, Parier, B., additional, Bernhard, J.C., additional, Cassuto, O., additional, Albiges, L., additional, Thibault, C., additional, Ingels, A., additional, Cherifi, F., additional, Waeckel, T., additional, Walz, J., additional, Flippot, R., additional, Geoffrois, L., additional, Gravis, G., additional, and Barthelemy, P., additional

Published
2024
Full Text
View/download PDF

20. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?

Author

Baboudjian, M., Gauthé, M., Barret, E., Brureau, L., Rocchi, P., Créhange, G., Dariane, C., Fiard, G., Fromont, G., Beauval, J.-B., Mathieu, R., Renard-Penna, R., Roubaud, G., Ruffion, A., Sargos, P., Rouprêt, M., and Ploussard, G.

Published
2022
Full Text
View/download PDF

21. Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative à propos des performances de la TEP/TDM en cas de récidive biochimique après prostatectomie radicale dans le cancer de la prostate et impact sur la prise en charge des patients

Author

Lasserre, M., Sargos, P., Barret, E., Beauval, J.-B., Brureau, L., Créhange, G., Dariane, C., Fiard, G., Fromont, G., Mathieu, R., Renard-Penna, R., Roubaud, G., Ruffion, A., Rouprêt, M., Ploussard, G., and Gauthé, M.

Published
2022
Full Text
View/download PDF

22. Analyse descriptive de la plus grande cohorte mondiale de patients atteints de cancer de la prostate résistant à la castration métastatique (CPRCM) traités en accès précoce par [177LU]LU-PSMA-617 en France : premières données en vie réelle

Author

Barthelemy, P., primary, Somme, F., additional, Olivier, P., additional, Massard, V., additional, Godbert, Y., additional, Roubaud, G., additional, Girault, S., additional, Abadie-Lacourtoisie, S., additional, Bailly, C., additional, Viala, C., additional, Flechon, A., additional, and Giraudet, A., additional

Published
2023
Full Text
View/download PDF

23. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

Author

Loriot, Y., Pagliaro, L., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.C., Malhaire, J.P., Linassier, C., Habibian, M., Martin, A.L., Journeau, F., Reckova, M., Logothetis, C., Laplanche, A., Le Teuff, G., Culine, S., and Fizazi, K.

Published
2017
Full Text
View/download PDF

26. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Author

Antonarakis, E.S., Park, S.H., Goh, J.C., Shin, S.J., Lee, J.L., Mehra, N., McDermott, R., Sala-Gonzalez, N., Fong, P.C., Greil, R., Retz, M., Sade, J.P., Yanez, P., Huang, Y.H., Begbie, S.D., Gafanov, R.A., Santis, M. de, Rosenbaum, E., Kolinsky, M.P., Rey, F., Chiu, K.Y., Roubaud, G., Kramer, G., Sumitomo, M., Massari, F., Suzuki, H., Qiu, P., Zhang, J., Kim, J., Poehlein, C.H., Yu, E.Y., Antonarakis, E.S., Park, S.H., Goh, J.C., Shin, S.J., Lee, J.L., Mehra, N., McDermott, R., Sala-Gonzalez, N., Fong, P.C., Greil, R., Retz, M., Sade, J.P., Yanez, P., Huang, Y.H., Begbie, S.D., Gafanov, R.A., Santis, M. de, Rosenbaum, E., Kolinsky, M.P., Rey, F., Chiu, K.Y., Roubaud, G., Kramer, G., Sumitomo, M., Massari, F., Suzuki, H., Qiu, P., Zhang, J., Kim, J., Poehlein, C.H., and Yu, E.Y.

Abstract

Contains fulltext : 295958.pdf (Publisher’s version ) (Open Access), PURPOSE: There is an unmet need for therapeutic options that prolong survival for patients with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase III, open-label KEYLYNK-010 study evaluated pembrolizumab plus olaparib versus a next-generation hormonal agent (NHA) for biomarker-unselected, previously treated mCRPC. METHODS: Eligible participants had mCRPC that progressed on or after abiraterone or enzalutamide (but not both) and docetaxel. Participants were randomly assigned (2:1) to pembrolizumab plus olaparib or NHA (abiraterone or enzalutamide). The dual primary end points were radiographic progression-free survival (rPFS) by blinded independent central review per Prostate Cancer Working Group-modified RECIST 1.1 and overall survival (OS). Time to first subsequent therapy (TFST) was a key secondary end point. Safety and objective response rate (ORR) were secondary end points. RESULTS: Between May 30, 2019, and July 16, 2021, 529 participants were randomly assigned to pembrolizumab plus olaparib and 264 to NHA. At final rPFS analysis, median rPFS was 4.4 months (95% CI, 4.2 to 6.0) with pembrolizumab plus olaparib and 4.2 months (95% CI, 4.0 to 6.1) with NHA (hazard ratio [HR], 1.02 [95% CI, 0.82 to 1.25]; P = .55). At final OS analysis, median OS was 15.8 months (95% CI, 14.6 to 17.0) and 14.6 months (95% CI, 12.6 to 17.3), respectively (HR, 0.94 [95% CI, 0.77 to 1.14]; P = .26). At final TFST analysis, median TFST was 7.2 months (95% CI, 6.7 to 8.1) versus 5.7 months (95% CI, 5.0 to 7.1), respectively (HR, 0.86 [95% CI, 0.71 to 1.03]). ORR was higher with pembrolizumab plus olaparib versus NHA (16.8% v 5.9%). Grade ≥3 treatment-related adverse events occurred in 34.6% and 9.0% of participants, respectively. CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occu

Published
2023

27. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Author

Selle, F., Wittnebel, S., Biron, P., Gravis, G., Roubaud, G., Bui, B.N., Delva, R., Bay, J.O., Fléchon, A., Geoffrois, L., Caty, A., Soares, D.G., de Revel, T., Fizazi, K., Gligorov, J., Micléa, J.M., Dubot, C., Provent, S., Temby, I., Gaulet, M., Horn, E., Brindel, I., and Lotz, J.P.

Published
2014
Full Text
View/download PDF

28. Hétérogénéité du cancer de la prostate de groupe de grade 4 diagnostiqué sur prostatectomie radicale

Author

Martini, A., primary, Touzani, A., additional, Beauval, J., additional, Ruffion, A., additional, Olivier, J., additional, Gasmi, A., additional, Dariane, C., additional, Thoulouzan, M., additional, Barret, E., additional, Brureau, L., additional, Fiard, G., additional, Roubaud, G., additional, Sargos, P., additional, Roumiguié, M., additional, Timsit, M., additional, Mathieu, R., additional, Villers, A., additional, Rouprêt, M., additional, Fromont, G., additional, and Ploussard, G., additional

Published
2022
Full Text
View/download PDF

29. L’intensification du traitement du cancer de la prostate métastatique hormonosensible (MHSPC) est devenue un standard de prise en charge en France (étude profile)

Author

Helissey, C., primary, Maillet, D., additional, Narciso, B., additional, Berdah, J., additional, Ouzaid, I., additional, Hilgers, W., additional, Fiard, G., additional, Dubergé, T., additional, Jovenin, N., additional, Topart, D., additional, Beauval, J., additional, Didier, N., additional, and Roubaud, G., additional

Published
2022
Full Text
View/download PDF

30. Comparaison de la survie globale à 4 ans des patients ayant un cancer de la prostate métastatique synchrone ou métachrone issus d’une étude « en vie réelle »

Author

Bajeot, A., primary, Rebillard, X., additional, Charles, T., additional, Gaschignard, N., additional, Villers, A., additional, Olivier, J., additional, Cormier, L., additional, Roubaud, G., additional, Van Glabeke, E., additional, Descotes, J., additional, Lechevallier, E., additional, Avances, C., additional, Bruyère, F., additional, Neuzillet, Y., additional, Brouzes, H., additional, Ruffion, A., additional, Brureau, L., additional, Gamé, X., additional, Soulié, M., additional, and Roumiguié, M., additional

Published
2022
Full Text
View/download PDF

33. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

Author

Martin Romano, P., primary, Roubaud, G., additional, Lavaud, P., additional, Cabart, M., additional, Pages, A., additional, Vasseur, D., additional, Colomba, E., additional, Cousin, S., additional, Toulmonde, M., additional, Grellety, T., additional, Castel Ajgal, Z., additional, Chabanon, R., additional, Parpaleix, A., additional, Buzzatti, G., additional, Fizazi, K., additional, Gomez-Roca, C.A., additional, Italiano, A., additional, Loriot, Y., additional, and Postel-Vinay, S., additional

Published
2022
Full Text
View/download PDF

34. 1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

Author

Gravis Mescam, G., primary, Maldonado, X., additional, Roubaud, G., additional, McDermott, R.S., additional, Flechon, A., additional, Tombal, B., additional, Supiot, S., additional, Berthold, D.R., additional, Philippe, R., additional, Kacso, G., additional, Calabrò, F., additional, Berdah, J.F., additional, Hasbini, A., additional, Silva, M., additional, Thiery-Vuillemin, A., additional, Rodriguez-Vida, A., additional, McCaffrey, J.A., additional, Ribault, H., additional, Foulon, S., additional, and Fizazi, K., additional

Published
2022
Full Text
View/download PDF

35. 1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

Author

Bernard-Tessier, A., primary, Cancel, M., additional, Tombal, B., additional, Roubaud, G., additional, Carles Galceran, J., additional, Flechon, A., additional, McDermott, R.S., additional, Supiot, S., additional, Berthold, D.R., additional, Philippe, R., additional, Kacso, G., additional, Gravis Mescam, G., additional, Calabrò, F., additional, Berdah, J.F., additional, Hasbini, A., additional, Ricci, F., additional, Hennequin, C., additional, Ribault, H., additional, Foulon, S., additional, and Fizazi, K., additional

Published
2022
Full Text
View/download PDF

36. 1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

Author

Fizazi, K., primary, Bernard-Tessier, A., additional, Barthelemy, P., additional, Utriainen, T., additional, Roubaud, G., additional, Flechon, A., additional, van der Voet, J.C.M., additional, Gravis Mescam, G., additional, Ratta, R., additional, Jones, R.H., additional, Parikh, O.A., additional, Tanner, M.M.E., additional, Garratt, C., additional, Nevalaita, L., additional, Pohjanjousi, P., additional, Ikonen, T., additional, Antonarakis, E.S., additional, and Cook, N., additional

Published
2022
Full Text
View/download PDF

40. 1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

Author

Fizazi, K., Morris, M.J., Shore, N.D., Chi, K.N., Crosby, M., de Bono, J.S., Herrmann, K., Roubaud, G., Nagarajah, J., Fleming, M.T., Lewis, B., Nordquist, L.T., Castellano Gauna, D.E., Carnahan, N., Ghebremariam, S., Hertelendi, M., and Sartor, O.

Published
2024
Full Text
View/download PDF

42. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study

Author

Roubaud, G., Oezgueroglu, Mustafa, Penel, Nicolas, Matsubara, Nobuaki, Mehra, N., Kolinsky, M.P., Rosario, Paula Del, Fizazi, K., Roubaud, G., Oezgueroglu, Mustafa, Penel, Nicolas, Matsubara, Nobuaki, Mehra, N., Kolinsky, M.P., Rosario, Paula Del, and Fizazi, K.

Abstract

Contains fulltext : 251378.pdf (Publisher’s version ) (Open Access)

Published
2022

44. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

Author

Fizazi, K, Foulon, S, Carles, J, Roubaud, G, McDermott, R, Flechon, A, Tombal, B, Supiot, S, Berthold, D, Ronchin, P, Kacso, G, Gravis, G, Calabro, F, Berdah, JF, Hasbini, A, Silva, M, Thiery-Vuillemin, A, Latorzeff, I, Mourey, L, Laguerre, B, Abadie-Lacourtoisie, S, Martin, E, El Kouri, C, Escande, A, Rosello, A, Magne, N, Schlurmann, F, Priou, F, Chand-Fouche, ME, Freixa, SV, Jamaluddin, M, Rieger, I, and Bossi, A

Abstract

Background Current standard of care for metastatic castration-sensitive prostate cancer supplements androgen deprivation therapy with either docetaxel, second-generation hormonal therapy, or radiotherapy. We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care. Methods We conducted an open-label, randomised, phase 3 study with a 2 x 2 factorial design (PEACE-1) at 77 hospitals across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland. Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 due to bone pain). Participants were randomly assigned (1: 1:1:1) to standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m(2) once every 3 weeks), standard of care plus radiotherapy, standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily), or standard of care plus radiotherapy plus abiraterone. Neither the investigators nor the patients were masked to treatment allocation. The coprimary endpoints were radiographic progression-free survival and overall survival. Abiraterone efficacy was first assessed in the overall population and then in the population who received androgen deprivation therapy with docetaxel as standard of care (population of interest). This study is ongoing and is registered with ClinicalTrials.gov, NCT01957436. Findings Between Nov 27, 2013, and Dec 20, 2018, 1173 patients were enrolled (one patient subsequently withdrew consent for analysis of his data) and assigned to receive standard of care (n=296), standard of care plus radiotherapy (n=293), standard of care plus abiraterone (n=292), or standard of care plus radiotherapy plus abiraterone (n=291). Median follow-up was 3.5 years (IQR 2.8-4.6) for radiographic progression-free survival and 4.4 years (3.5-5.4) for overall survival. Adjusted Cox regression modelling revealed no interaction between abiraterone and radiotherapy, enabling the pooled analysis of abiraterone efficacy. In the overall population, patients assigned to receive abiraterone (n=583) had longer radiographic progression-free survival (hazard ratio [HR] 0.54, 99.9% CI 0.41-0.71; p

Published
2022

47. A0841 - Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: Oncological outcomes and predictive factors of surgical difficulties

Author

Pignot, G., Margue, G., Bigot, P., Lang, H., Balssa, L., Roubaud, G., Borchiellini, D., Bensalah, K., Schlürmann, F., Ladoire, S., Parier, B., Bernhard, J.C., Cassuto, O., Albiges, L., Thibault, C., Ingels, A., Cherifi, F., Waeckel, T., Walz, J., Flippot, R., Geoffrois, L., Gravis, G., and Barthelemy, P.

Published
2024
Full Text
View/download PDF

48. Résultats oncologiques de la néphrectomie différée après réponse complète à l’immunothérapie pour cancer du rein métastatique au diagnostic

Author

Pignot, G., primary, Thiery-vuillemin, A., additional, Walz, J., additional, Lang, H., additional, Balssa, L., additional, Leblanc, L., additional, Borchiellini, D., additional, Parier, B., additional, Albiges, L., additional, Bensalah, K., additional, Schlurmann, F., additional, Mourey, E., additional, Bigot, P., additional, Ingels, A., additional, Bernhard, J.C., additional, Piechaud, T., additional, Roubaud, G., additional, Klifa, D., additional, Gravis, G., additional, and Barthelemy, P., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results